Detalhe da pesquisa
1.
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
BMC Cancer
; 19(1): 572, 2019 Jun 13.
Artigo
Inglês
| MEDLINE | ID: mdl-31196032